[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-342649-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-342649-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","plasma-levels-of-pentraxin-3-a-potential-prognostic-biomarker-in-urinary-bladder-cancer-patients","Plasma Levels of Pentraxin 3 - A Potential Prognostic Biomarker in Urinary Bladder Cancer Patients","","Urinary bladder cancer (BC) is a major health issue, making novel biomarkers essential for early detection and outcome prediction. This study assessed whether plasma pentraxin 3 (PTX3) can serve as a biomarker for BC patients. PTX3 plasma levels were measured in 118 BC patients and 50 controls using ELISA, showing higher levels in BC than controls. PTX3 offered limited diagnostic value but potential prognostic significance, as elevated levels were associated with metastatic progression during follow-up.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/plasma-levels-of-pentraxin-3-a-potential-prognostic-biomarker-in-urinary-bladder-cancer-patients/342649/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/plasma-levels-of-pentraxin-3-a-potential-prognostic-biomarker-in-urinary-bladder-cancer-patients/342649.png","ImageObject",300,407,{"name":42,"@type":43},"Olivia Brown","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the purpose of measuring plasma PTX3 in urinary bladder cancer patients?","Question",{"text":63,"@type":64},"To determine whether plasma PTX3 can function as a biomarker for patients with urinary bladder cancer, supporting early detection and outcome prediction.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were PTX3 plasma levels measured in the study?",{"text":68,"@type":64},"Plasma PTX3 levels were determined in 118 BC patients and 50 controls by ELISA.",{"name":70,"@type":61,"acceptedAnswer":71},"Do the results suggest PTX3 is useful diagnostically or prognostically?",{"text":72,"@type":64},"The diagnostic value appears limited, with differences mainly observed between muscle-invasive disease and controls, while prognostic potential is suggested by higher PTX3 levels in patients who developed metastatic disease during follow-up.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},342649,1790115112,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":115,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Communication  \nPlasma Levels of Pentraxin 3: A Potential Prognostic Biomarker in Urinary Bladder Cancer Patients  \nAnders Vikerfors *, Sabina Davidsson , Jessica Carlsson  and Tomas Jerlström  \nCitation: Vikerfors, A.; Davidsson, S.; Carlsson, J.; Jerlström, T. Plasma Levels of Pentraxin 3: A Potential Prognostic Biomarker in Urinary Bladder Cancer Patients. Int. J. Mol. Sci. 2024, 25, 3473. [https://](https://)[ ](https://)[doi.org/10.3390/ijms25063473](doi.org/10.3390/ijms25063473)  \nAcademic Editors: Thomas Otto, Thorsten Ecke and Florence  \nL. Le-Calvez Kelm  \nReceived: 26 February 2024  \nRevised: 12 March 2024  \nAccepted: 15 March 2024  \nPublished: 20 March 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \nDepartment of Urology, Faculty of Medicine and Health, Örebro University, 703 62 Örebro, Sweden;  \n[sabina.davidsson@regionorebrolan.se](sabina.davidsson@regionorebrolan.se) (S.D.); [jessica.carlsson@regionorebrolan.se](jessica.carlsson@regionorebrolan.se) (J.C.);  \n[tomas.jerlstrom@regionorebrolan.se](tomas.jerlstrom@regionorebrolan.se) (T.J.)  \n* Correspondence: [anders.vikerfors@regionorebrolan.se](anders.vikerfors@regionorebrolan.se)  \nAbstract: Urinary bladder cancer (BC) represents a major health issue, and identifying novel biomarkers for early disease detection and outcome prediction is paramount. It has already been established that the immune system plays a role in tumour initiation and progression in which the inflammatory marker pentraxin 3 (PTX3) might be involved, presenting a variety of functions in different cancers. The aim of this study was to investigate whether plasma levels of PTX3 could be used as a biomarker for patients with BC. Plasma levels of PTX3 were determined in 118 BC patients and 50 controls by ELISA. Patients with BC had significantly higher PTX3 levels compared to controls. The value asa diagnostic biomarker is probably limited, however, since no significant difference in PTX3 levels was seen between patients with non-muscle-invasive BC and controls; they were seen only between patients with muscle-invasive disease and controls. However, the potential value of PTX3 as a prognostic biomarker was indicated by significantly higher PTX3 levels in patients who developed metastatic disease during follow-up compared to patients who did not develop metastatic disease. The conclusions from this study are that plasma levels of PTX3 have limited value as a diagnostic biomarker, although they have potential as a prognostic biomarker for patients with BC.  \nKeywords: urinary bladder cancer; plasma biomarker; diagnostic; prognostic; PTX3  \n1. Introduction  \nUrinary bladder cancer (BC) is the ninth most common cancer worldwide and the thirteenth deadliest [1] . The majority of cases are low-grade and non-muscle-invasive bladder cancers (NMIBCs) at presentation [2] with a relatively good prognosis. However, approximately 15% of NMIBCs progress to a muscle-invasive bladder cancer (MIBC), which is more aggressive and associated with worse prognosis. If untreated, the 5-year survival rate for these patients is low (20.9%), and it is even lower with the presence of visceral metastases (6.8%) [3] . The most common type of BC in developed countries is urothelial carcinomas, although some rare histological subtypes exist, including squamous, glandular, or sarcomatoid cell features. The high incidence and recurrence rate of BC, demanding long-term patient follow-up, makes BC one of the most expensive malignancies to manage from a health-economic perspective [4] . In Sweden, BC survival rates have improved in the past few decades; however, incidence has increased and mortality remains relatively un","cbCaiuZv4XUyW7Vd","https://ap.wps.com/l/cbCaiuZv4XUyW7Vd","pdf",424993,"English","# Introduction\n## Rationale for biomarker development\n## Immunity, inflammation, and pentraxins\n## PTX3 biology and cancer relevance","[{\"question\":\"What is the purpose of measuring plasma PTX3 in urinary bladder cancer patients?\",\"answer\":\"To determine whether plasma PTX3 can function as a biomarker for patients with urinary bladder cancer, supporting early detection and outcome prediction.\"},{\"question\":\"How were PTX3 plasma levels measured in the study?\",\"answer\":\"Plasma PTX3 levels were determined in 118 BC patients and 50 controls by ELISA.\"},{\"question\":\"Do the results suggest PTX3 is useful diagnostically or prognostically?\",\"answer\":\"The diagnostic value appears limited, with differences mainly observed between muscle-invasive disease and controls, while prognostic potential is suggested by higher PTX3 levels in patients who developed metastatic disease during follow-up.\"}]","Plasma Levels of Pentraxin 3 - A Potential Prognostic Biomarker in Urinary Bladder Cancer Patients | PDF",1790047544,23,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7f5312f804226372bb6da1f1acc1a945.webp",983,1390,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d2d8e62bd1f368d11b6af24f49e09e38.webp",982,1388,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d664a9027ae0ab7f7ccd88ef38886018.webp",981,1387,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3e654fa78fc2dcbafdb0e76b2df542a8.webp",980,1385]